Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one or more phase I trials of various investigational...
Saved in:
| Published in | Molecular cancer research Vol. 19; no. 3; pp. 395 - 402 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.03.2021
|
| Online Access | Get full text |
| ISSN | 1541-7786 1557-3125 1557-3125 |
| DOI | 10.1158/1541-7786.MCR-20-0751 |
Cover
| Abstract | Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one or more phase I trials of various investigational therapies. Patients' tumors or circulating tumor DNA were analyzed by next-generation sequencing. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%.
, and
alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, respectively. Alterations in
were almost mutually exclusive of
. More than half (64%) of patients with an
alt received an FGFR inhibitor, 67% of which achieved disease control. Among patients with urothelial carcinoma histology, those harboring a
alteration had a shorter median progression-free survival (PFS) compared with those whose tumors carry wild-type
. The reverse relationship was observed in patients harboring an
alteration. IMPLICATIONS: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinical trials and their survival outcomes correlate with the genetic profile of the tumor. VISUAL OVERVIEW: http://mcr.aacrjournals.org/content/molcanres/19/3/395/F1.large.jpg. |
|---|---|
| AbstractList | Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one or more phase I trials of various investigational therapies. Patients' tumors or circulating tumor DNA were analyzed by next-generation sequencing. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%.
, and
alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, respectively. Alterations in
were almost mutually exclusive of
. More than half (64%) of patients with an
alt received an FGFR inhibitor, 67% of which achieved disease control. Among patients with urothelial carcinoma histology, those harboring a
alteration had a shorter median progression-free survival (PFS) compared with those whose tumors carry wild-type
. The reverse relationship was observed in patients harboring an
alteration. IMPLICATIONS: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinical trials and their survival outcomes correlate with the genetic profile of the tumor. VISUAL OVERVIEW: http://mcr.aacrjournals.org/content/molcanres/19/3/395/F1.large.jpg. Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one or more phase I trials of various investigational therapies. Patients' tumors or circulating tumor DNA were analyzed by next-generation sequencing. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%. TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, respectively. Alterations in FGFR3 were almost mutually exclusive of TP53. More than half (64%) of patients with an FGFR alt received an FGFR inhibitor, 67% of which achieved disease control. Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter median progression-free survival (PFS) compared with those whose tumors carry wild-type TP53. The reverse relationship was observed in patients harboring an FGFR alteration. IMPLICATIONS: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinical trials and their survival outcomes correlate with the genetic profile of the tumor. VISUAL OVERVIEW: http://mcr.aacrjournals.org/content/molcanres/19/3/395/F1.large.jpg.Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one or more phase I trials of various investigational therapies. Patients' tumors or circulating tumor DNA were analyzed by next-generation sequencing. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%. TP53, ERBB2, PI3KCA, FGFR3, and ARID1A alterations were detected in 66%, 29%, 27%, 24%, and 22% of all patients, respectively. Alterations in FGFR3 were almost mutually exclusive of TP53. More than half (64%) of patients with an FGFR alt received an FGFR inhibitor, 67% of which achieved disease control. Among patients with urothelial carcinoma histology, those harboring a TP53 alteration had a shorter median progression-free survival (PFS) compared with those whose tumors carry wild-type TP53. The reverse relationship was observed in patients harboring an FGFR alteration. IMPLICATIONS: Patients with platinum-refractory mBC derive clinical benefit from participating in early-phase clinical trials and their survival outcomes correlate with the genetic profile of the tumor. VISUAL OVERVIEW: http://mcr.aacrjournals.org/content/molcanres/19/3/395/F1.large.jpg. |
| Author | Karp, Daniel Filip, Janku Tannir, Nizar M. Campbell, Erick Siefker-Radtke, Arlene O. Piha-Paul, Sarina Shah, Amishi Y. Hong, David S. Msaouel, Pavlos Alhalabi, Omar Pant, Shubham Meric-Bernstam, Funda Campbell, Matthew T. Roszik, Jason Le, Hung Hahn, Andrew W. Subbiah, Vivek Andreev-Drakhlin, Alexander Y. Naing, Aung Yap, Timothy A. Fu, Siqing Gao, Jianjun |
| Author_xml | – sequence: 1 givenname: Omar orcidid: 0000-0002-9658-2206 surname: Alhalabi fullname: Alhalabi, Omar – sequence: 2 givenname: Andrew W. orcidid: 0000-0002-4153-205X surname: Hahn fullname: Hahn, Andrew W. – sequence: 3 givenname: Pavlos orcidid: 0000-0001-6505-8308 surname: Msaouel fullname: Msaouel, Pavlos – sequence: 4 givenname: Alexander Y. surname: Andreev-Drakhlin fullname: Andreev-Drakhlin, Alexander Y. – sequence: 5 givenname: Funda surname: Meric-Bernstam fullname: Meric-Bernstam, Funda – sequence: 6 givenname: Aung orcidid: 0000-0002-4803-8513 surname: Naing fullname: Naing, Aung – sequence: 7 givenname: Sarina surname: Piha-Paul fullname: Piha-Paul, Sarina – sequence: 8 givenname: Janku orcidid: 0000-0002-8123-4065 surname: Filip fullname: Filip, Janku – sequence: 9 givenname: Shubham surname: Pant fullname: Pant, Shubham – sequence: 10 givenname: Timothy A. orcidid: 0000-0002-2154-3309 surname: Yap fullname: Yap, Timothy A. – sequence: 11 givenname: David S. orcidid: 0000-0001-8721-1609 surname: Hong fullname: Hong, David S. – sequence: 12 givenname: Siqing surname: Fu fullname: Fu, Siqing – sequence: 13 givenname: Daniel surname: Karp fullname: Karp, Daniel – sequence: 14 givenname: Erick orcidid: 0000-0003-1915-4491 surname: Campbell fullname: Campbell, Erick – sequence: 15 givenname: Hung surname: Le fullname: Le, Hung – sequence: 16 givenname: Matthew T. orcidid: 0000-0003-1915-4491 surname: Campbell fullname: Campbell, Matthew T. – sequence: 17 givenname: Amishi Y. surname: Shah fullname: Shah, Amishi Y. – sequence: 18 givenname: Nizar M. surname: Tannir fullname: Tannir, Nizar M. – sequence: 19 givenname: Arlene O. surname: Siefker-Radtke fullname: Siefker-Radtke, Arlene O. – sequence: 20 givenname: Jianjun surname: Gao fullname: Gao, Jianjun – sequence: 21 givenname: Jason orcidid: 0000-0002-4561-6170 surname: Roszik fullname: Roszik, Jason – sequence: 22 givenname: Vivek orcidid: 0000-0002-6064-6837 surname: Subbiah fullname: Subbiah, Vivek |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33323389$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkTtv3DAQhInAgV_xT0ig0o1sPkRSQqpY8AvwwYfAqYk9amUz4IkXkir8703BlxRp3Oxs8c0UMyfkYAoTEvKV0QvGZHvJZMNqrVt1sep_1pzWVEv2iRwzKXUtGJcHy79njshJSr8p5ZRpdUiOhBBciLY7JnEVPNrZQ6zWMYzOu-m5CmO1wgwpQ3a2uvIwDBirHiZb5Bqif63XL5Cw6gvuLPjqKbpy1xCLwe1gyqnE4eDs8pQUnHL1OGcbtpi-kM8j-IRnez0lv26un_q7-uHx9r7_8VBboWWuOadaSyX1CFaBolZ1A6LGUTebDWfQIOUDp7zjirdgdQOtYhvbQQdtIzUTp-T8PXcXw58ZUzZblyx6DxOGORneaKoEl60s6Lc9Om-2OJhddFuIr-ZvTwWQ74CNIaWI4z-EUbPsYZauzdK1KXsYTs2yR_F9_89n3dJqmHIE5z9wvwEUsZC1 |
| CitedBy_id | crossref_primary_10_3389_fonc_2022_1011885 crossref_primary_10_1016_j_euf_2021_07_016 crossref_primary_10_3390_cancers15072149 crossref_primary_10_1016_j_urolonc_2024_01_016 crossref_primary_10_1016_j_humpath_2021_04_001 crossref_primary_10_1016_j_modpat_2023_100120 |
| Cites_doi | 10.1016/j.jmoldx.2016.09.011 10.1038/nbt.2696 10.1016/S1470-2045(05)70315-6 10.1016/S0140-6736(16)00561-4 10.1126/scisignal.2004088 10.1016/j.eururo.2015.08.034 10.1038/nature13904 10.1158/2159-8290.CD-12-0095 10.1016/j.cell.2017.09.007 10.1016/S1470-2045(17)30065-7 10.1016/j.eururo.2008.06.013 10.1200/JCO.2011.34.8433 10.1016/S1470-2045(17)30900-2 10.1200/JCO.2019.37.15_suppl.e14614 10.1016/S0140-6736(16)32455-2 10.1056/NEJMoa1817323 10.1200/JCO.2017.73.7916 10.3322/caac.21551 10.1016/S1470-2045(16)30496-X 10.1056/NEJM199411103311903 10.1038/sj.bjc.6601118 10.1200/JCO.2019.37.18_suppl.LBA108 10.1371/journal.pone.0140712 10.1093/annonc/mdx692 |
| ContentType | Journal Article |
| Copyright | 2020 American Association for Cancer Research. |
| Copyright_xml | – notice: 2020 American Association for Cancer Research. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1158/1541-7786.MCR-20-0751 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1557-3125 |
| EndPage | 402 |
| ExternalDocumentID | 33323389 10_1158_1541_7786_MCR_20_0751 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U01 CA180964 – fundername: NCATS NIH HHS grantid: UL1 TR003167 – fundername: NCATS NIH HHS grantid: UL1 TR000371 – fundername: NCI NIH HHS grantid: R01 CA242845 |
| GroupedDBID | --- 123 18M 2FS 2WC 34G 39C 53G 5RE 5VS AAJMC AAYXX ACGFO ACPRK ADBBV ADCOW AENEX AFHIN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 IH2 KQ8 L7B OK1 QTD RCR RHI TR2 W8F WOQ YKV .55 .GJ 3O- ABEFU AFFNX C1A H13 H~9 MVM NPM WHG X7M ZGI 7X8 |
| ID | FETCH-LOGICAL-c375t-220775657fac6a60c69dee7ef74bb21a4e02d20292628ac74a861bc9a9a845713 |
| ISSN | 1541-7786 1557-3125 |
| IngestDate | Fri Sep 05 09:41:47 EDT 2025 Thu Apr 03 07:04:44 EDT 2025 Thu Apr 24 23:03:31 EDT 2025 Tue Jul 01 04:31:29 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | 2020 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c375t-220775657fac6a60c69dee7ef74bb21a4e02d20292628ac74a861bc9a9a845713 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-4803-8513 0000-0001-6505-8308 0000-0002-9658-2206 0000-0002-4153-205X 0000-0003-1915-4491 0000-0002-4561-6170 0000-0002-2154-3309 0000-0002-6064-6837 0000-0001-8721-1609 0000-0002-8123-4065 |
| PMID | 33323389 |
| PQID | 2470632585 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2470632585 pubmed_primary_33323389 crossref_primary_10_1158_1541_7786_MCR_20_0751 crossref_citationtrail_10_1158_1541_7786_MCR_20_0751 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-01 2021-03-00 20210301 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular cancer research |
| PublicationTitleAlternate | Mol Cancer Res |
| PublicationYear | 2021 |
| References | Lanman (2022060706520190900_bib18) 2015; 10 Williamson (2022060706520190900_bib17) 2019; 37 Bamias (2022060706520190900_bib1) 2018; 29 Chakravarty (2022060706520190900_bib21) 2017; 2017 Harvey (2022060706520190900_bib27) 2019; 37 van Oers (2022060706520190900_bib25) 2009; 55 Galsky (2022060706520190900_bib12) 2011; 29 Cerami (2022060706520190900_bib19) 2012; 2 Kim (2022060706520190900_bib26) 2017; 35 Gao (2022060706520190900_bib20) 2013; 6 Siegel (2022060706520190900_bib22) 2019; 69 Robertson (2022060706520190900_bib9) 2017; 171 Clark (2022060706520190900_bib14) 2003; 89 Balar (2022060706520190900_bib2) 2017; 389 Esrig (2022060706520190900_bib23) 1994; 331 Sharma (2022060706520190900_bib5) 2017; 18 Luthra (2022060706520190900_bib16) 2017; 19 Malats (2022060706520190900_bib24) 2005; 6 Powles (2022060706520190900_bib7) 2014; 515 Patel (2022060706520190900_bib13) 2018; 19 Apolo (2022060706520190900_bib6) 2017 Sharma (2022060706520190900_bib4) 2016; 17 Rosenberg (2022060706520190900_bib3) 2016; 387 Frampton (2022060706520190900_bib15) 2013; 31 Hahn (2022060706520190900_bib8) 2017 McConkey (2022060706520190900_bib10) 2016; 69 Loriot (2022060706520190900_bib11) 2019; 381 33649195 - Mol Cancer Res. 2021 Mar;19(3):359 |
| References_xml | – volume: 19 start-page: 255 year: 2017 ident: 2022060706520190900_bib16 article-title: A targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2016.09.011 – volume: 31 start-page: 1023 year: 2013 ident: 2022060706520190900_bib15 article-title: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing publication-title: Nat Biotechnol doi: 10.1038/nbt.2696 – volume: 6 start-page: 678 year: 2005 ident: 2022060706520190900_bib24 article-title: P53 as a prognostic marker for bladder cancer: a meta-analysis and review publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70315-6 – volume: 387 start-page: 1909 year: 2016 ident: 2022060706520190900_bib3 article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00561-4 – volume: 6 start-page: pl1 year: 2013 ident: 2022060706520190900_bib20 article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal publication-title: Sci Signal doi: 10.1126/scisignal.2004088 – volume: 69 start-page: 855 year: 2016 ident: 2022060706520190900_bib10 article-title: A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2015.08.034 – volume: 515 start-page: 558 year: 2014 ident: 2022060706520190900_bib7 article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer publication-title: Nature doi: 10.1038/nature13904 – volume: 2 start-page: 401 year: 2012 ident: 2022060706520190900_bib19 article-title: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0095 – volume: 171 start-page: 540 year: 2017 ident: 2022060706520190900_bib9 article-title: Comprehensive molecular characterization of muscle-invasive bladder cancer publication-title: Cell doi: 10.1016/j.cell.2017.09.007 – volume: 2017 start-page: PO.17.00011 year: 2017 ident: 2022060706520190900_bib21 article-title: OncoKB: a precision oncology knowledge base publication-title: JCO Precis Oncol – volume: 18 start-page: 312 year: 2017 ident: 2022060706520190900_bib5 article-title: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30065-7 – volume: 55 start-page: 650 year: 2009 ident: 2022060706520190900_bib25 article-title: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours publication-title: Eur Urol doi: 10.1016/j.eururo.2008.06.013 – volume: 29 start-page: 2432 year: 2011 ident: 2022060706520190900_bib12 article-title: Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2011.34.8433 – start-page: JCO2016716795 year: 2017 ident: 2022060706520190900_bib6 article-title: Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study publication-title: J Clin Oncol – volume: 19 start-page: 51 year: 2018 ident: 2022060706520190900_bib13 article-title: Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30900-2 – volume: 37 start-page: e14614 year: 2019 ident: 2022060706520190900_bib17 article-title: Analytical validation of the Oncomine Pan-Cancer Cell-Free Assay in a CLIA- and CAP-regulated laboratory for detection of solid tumor-derived variants in blood plasma publication-title: J Clin Oncol doi: 10.1200/JCO.2019.37.15_suppl.e14614 – volume: 389 start-page: 67 year: 2017 ident: 2022060706520190900_bib2 article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32455-2 – year: 2017 ident: 2022060706520190900_bib8 article-title: Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC) publication-title: ASCO Annual Meeting – volume: 381 start-page: 338 year: 2019 ident: 2022060706520190900_bib11 article-title: Erdafitinib in locally advanced or metastatic urothelial carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1817323 – volume: 35 start-page: 3737 year: 2017 ident: 2022060706520190900_bib26 article-title: Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement publication-title: J Clin Oncol doi: 10.1200/JCO.2017.73.7916 – volume: 69 start-page: 7 year: 2019 ident: 2022060706520190900_bib22 article-title: Cancer statistics, 2019 publication-title: CA Cancer J Clin doi: 10.3322/caac.21551 – volume: 17 start-page: 1590 year: 2016 ident: 2022060706520190900_bib4 article-title: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30496-X – volume: 331 start-page: 1259 year: 1994 ident: 2022060706520190900_bib23 article-title: Accumulation of nuclear p53 and tumor progression in bladder cancer publication-title: N Engl J Med doi: 10.1056/NEJM199411103311903 – volume: 89 start-page: 232 year: 2003 ident: 2022060706520190900_bib14 article-title: Survival analysis part I: basic concepts and first analyses publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601118 – volume: 37 start-page: LBA108 year: 2019 ident: 2022060706520190900_bib27 article-title: Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis publication-title: J Clin Oncol doi: 10.1200/JCO.2019.37.18_suppl.LBA108 – volume: 10 start-page: e0140712 year: 2015 ident: 2022060706520190900_bib18 article-title: Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA publication-title: PLoS One doi: 10.1371/journal.pone.0140712 – volume: 29 start-page: 361 year: 2018 ident: 2022060706520190900_bib1 article-title: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) publication-title: Ann Oncol doi: 10.1093/annonc/mdx692 – reference: 33649195 - Mol Cancer Res. 2021 Mar;19(3):359 |
| SSID | ssj0020176 |
| Score | 2.371574 |
| Snippet | Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 395 |
| Title | Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33323389 https://www.proquest.com/docview/2470632585 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1557-3125 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0020176 issn: 1541-7786 databaseCode: HH5 dateStart: 20020101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1557-3125 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020176 issn: 1541-7786 databaseCode: KQ8 dateStart: 20021101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1557-3125 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0020176 issn: 1541-7786 databaseCode: DIK dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1557-3125 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0020176 issn: 1541-7786 databaseCode: GX1 dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEIgXBANG-ZKReItSGsdxksfRgQaorEKdGE-R4zrqoLQoSyfBX8efxp3tuGEqH-MliqzmnPZ-Pd_Zv7sj5FmeK3REVFjGEQQogusw41juDrzlbKZUXlWGIPtOHB7zNyfJSa_3o8NaWjflQH3fmlfyP1qFMdArZsleQrNeKAzAPegXrqBhuP6Tjsdtb1vk-1enC8dgHutGYqLQqQpeLNCy1MEIlVsHppxxOJnD0hWM2pzIqWncMZGOYI28mEmN5zd4Y8uuBkfrBr6A4xt-uji7stJd4SC_wbyPh_GyNHyBoy-y3li7-XJDpgw-DLzWz-RqbWkDE3m-WHl_33xSn4cHtfw8dy3mfWpO8HHQ3btgHfJWa255FGIFO7saubEEd05tOrS30XkHi3HH4Ma2Radbu7nJ3t6yLCSY6uBnG4xH7wFIIbhL0WYdbM_-LyyPnrRowqUkK1BMgWIKEFOwYYFirpCrLBUCe2gcvH7rQ36wdya_rZ3Z5ZCBmOdb3-ZX7-g3IY9xfaa3yE0Xs9B9C8DbpKeXu-Sa7WL6bZdcHzt-xh1Se0xQj0i6qugGkdQhklpE0g4iaYtIahBJu4ikLSKpQyRtEXmXHL96OR0dhq6rR6jiNGlCxrDqokjSSiohxVCJfKZ1qquUlyWLJNdDNgOwYCHLTKqUy0xEpcplLsGKpFF8j-wsV0t9n9DZkOkkn5WV5IyrjEmdD6tKQgihlBCV7BPe_pqFciXvsfPKovijLvtk4B_7amu-_O2Bp62qCrDOeOQml3q1PisYTyEGYBCT98me1aEXGccxiyFeeHDZ6R6SG5s_0yOy09Rr_Rhc46Z8YtD3E-Tis90 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+Profiling+of+Metastatic+Bladder+Cancer+Early-Phase+Clinical+Trial+Participants+Predicts+Patient+Outcomes&rft.jtitle=Molecular+cancer+research&rft.au=Alhalabi%2C+Omar&rft.au=Hahn%2C+Andrew+W.&rft.au=Msaouel%2C+Pavlos&rft.au=Andreev-Drakhlin%2C+Alexander+Y.&rft.date=2021-03-01&rft.issn=1541-7786&rft.eissn=1557-3125&rft.volume=19&rft.issue=3&rft.spage=395&rft.epage=402&rft_id=info:doi/10.1158%2F1541-7786.MCR-20-0751&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1541_7786_MCR_20_0751 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1541-7786&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1541-7786&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1541-7786&client=summon |